-transparent.png){kind=logo}
Thirteen male patients with a history of duodenal ulcer were given 150 mg RP 40 749 or placebo tablets at bedtime in a double-blind crossover study. The medication was given for two periods of 10 days with an 11-day wash-out period between. pH and pepsin concentrations were determined each hour in aspirates of gastric juice for 24 h on day 1, 10, 22, 31, and a 2-h collection of gastric juice was examined in the middle of the treatment and wash-out periods. At defined hours blood samples were examined for gastrin, somatostatin, and pancreatic polypeptide (PP) by radioimmunological methods, and concentrations of RP 40 749 were determined in blood and gastric juice. Meals were served at fixed hours on days 1, 10, 22, and 31. After treatment with RP 40 749 a highly significant elevation of pH was found after the 1st day compared with placebo, most pronounced during night hours. The pepsin activity was slightly elevated. The serum concentrations of gastrin were increased and those of somatostatin and PP decreased during the first 3-4 h after medication, with a subsequent normalization. No side effects were observed.
J Myren, and
R Stave, and
J Mosvold, and
L E Hanssen, and
P Linnestad, and
M Osnes, and
S Larsen, and
S Berstad, and
K Valnes, and
S Lorentzen-Lund
June 1968,
The American journal of digestive diseases,
J Myren, and
R Stave, and
J Mosvold, and
L E Hanssen, and
P Linnestad, and
M Osnes, and
S Larsen, and
S Berstad, and
K Valnes, and
S Lorentzen-Lund
January 1986,
European journal of clinical pharmacology,
J Myren, and
R Stave, and
J Mosvold, and
L E Hanssen, and
P Linnestad, and
M Osnes, and
S Larsen, and
S Berstad, and
K Valnes, and
S Lorentzen-Lund
January 1985,
Drugs under experimental and clinical research,
J Myren, and
R Stave, and
J Mosvold, and
L E Hanssen, and
P Linnestad, and
M Osnes, and
S Larsen, and
S Berstad, and
K Valnes, and
S Lorentzen-Lund
February 1988,
Wiener medizinische Wochenschrift (1946),
J Myren, and
R Stave, and
J Mosvold, and
L E Hanssen, and
P Linnestad, and
M Osnes, and
S Larsen, and
S Berstad, and
K Valnes, and
S Lorentzen-Lund
April 1984,
Gastroenterologie clinique et biologique,
J Myren, and
R Stave, and
J Mosvold, and
L E Hanssen, and
P Linnestad, and
M Osnes, and
S Larsen, and
S Berstad, and
K Valnes, and
S Lorentzen-Lund
September 1986,
Gut,
J Myren, and
R Stave, and
J Mosvold, and
L E Hanssen, and
P Linnestad, and
M Osnes, and
S Larsen, and
S Berstad, and
K Valnes, and
S Lorentzen-Lund
January 1998,
Klinicheskaia meditsina,
J Myren, and
R Stave, and
J Mosvold, and
L E Hanssen, and
P Linnestad, and
M Osnes, and
S Larsen, and
S Berstad, and
K Valnes, and
S Lorentzen-Lund
July 1994,
Digestive diseases and sciences,
J Myren, and
R Stave, and
J Mosvold, and
L E Hanssen, and
P Linnestad, and
M Osnes, and
S Larsen, and
S Berstad, and
K Valnes, and
S Lorentzen-Lund
January 2006,
Klinicheskaia meditsina,
J Myren, and
R Stave, and
J Mosvold, and
L E Hanssen, and
P Linnestad, and
M Osnes, and
S Larsen, and
S Berstad, and
K Valnes, and
S Lorentzen-Lund
April 1984,
Lancet (London, England),
